XL184 free base 10mg 10mg | Purity Not Available
Adooq Bioscience
XL184 free base (Cabozantinib) is a small molecule designed to inhibit multiple receptor tyrosine kinases, specifically MET and VEGFR2.
More Information Supplier PageXL184 free base (Cabozantinib) is a small molecule designed to inhibit multiple receptor tyrosine kinases, specifically MET and VEGFR2.
More Information Supplier PageXL147 is a potent, selective and orally bioavailable small molecule inhibitor of class I phosphatidylinositol 3 kinase (PI3K) with potential antineoplastic activity.
More Information Supplier PageXL147 is a potent, selective and orally bioavailable small molecule inhibitor of class I phosphatidylinositol 3 kinase (PI3K) with potential antineoplastic activity.
More Information Supplier PageXL147 is a potent, selective and orally bioavailable small molecule inhibitor of class I phosphatidylinositol 3 kinase (PI3K) with potential antineoplastic activity.
More Information Supplier PageXL147 is a potent, selective and orally bioavailable small molecule inhibitor of class I phosphatidylinositol 3 kinase (PI3K) with potential antineoplastic activity.
More Information Supplier PageXAV 939 is a TNKS inhibitor (IC50 values are 0.011 and 0.004 ??M for TNKS1 and TNKS2 respectively).
More Information Supplier PageXAV 939 is a TNKS inhibitor (IC50 values are 0.011 and 0.004 ??M for TNKS1 and TNKS2 respectively).
More Information Supplier PageWYE-354 is a potent cell-permeable inhibitor of mTOR (IC50 = 4.3 nM) which blocks signaling through both mTOR complex 1 (mTORC1) and mTORC2. It is a much weaker inhibitor of PI3K ?? (IC50 = 1026 nM) and other kinases.
More Information Supplier PageWYE-354 is a potent cell-permeable inhibitor of mTOR (IC50 = 4.3 nM) which blocks signaling through both mTOR complex 1 (mTORC1) and mTORC2. It is a much weaker inhibitor of PI3K ?? (IC50 = 1026 nM) and other kinases.
More Information Supplier PageWP1130 (Degrasyn) is a novel selective small molecular deubiquitinase inhibitor and a Bcr/Abl destruction pathway activator that specifically and rapidly down-regulates both wild-type and mutant Bcr/Abl protein without affecting bcr/abl gene expression in chronic myelogenous leukemia (CML) cells.
More Information Supplier Page